Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
J. M. Binley, E. Crooks, F. Almanza, A. D'Addabbo, E. Duggan, J. Zhang, K. Wagh, H. Mou, J. Allen, A. Thomas, K. Osawa, B. Korber, Y. Tsybovsky, E. Cale, J. Nolan, , L. Verkoczy
This paper engineers HIV-1 envelope trimers with enhanced V2 and fusion peptide neutralization sensitivity for vaccine development.
bioRxiv · Jul 20, 2021Immunology